Vitrakvi works only on cancers with abnormal NTRK

Vitrakvi works only on cancers with abnormal NTRK gene fusions. Those NTRK gene fusions produce tyrosine kinases that promote tumor growth. Blockade of CCR5 stops the kinase signaling pathway shutting down that route of tumor growth.

So far with almost every cancer drug brought up leronlimab has covered that specific MOA. You could pick out a half dozen cancer drugs at random and most likely leronlimab does what they all do and more.